Company Overview and News

15
New Strong Sell Stocks for August 29th

2018-08-29 zacks - 1
Washington Prime Group Inc. (WPG - Free Report) is a retail REIT. The Zacks Consensus Estimate for its current year earnings has been revised 0.7% downward over the last 30 days.
TSNU EVLV SSL DY UCTI URBN 500570 TSN TATAMOTORS UCTT TTM

5
New Strong Sell Stocks for August 27th

2018-08-27 zacks - 1
ABM Industries Incorporated (ABM - Free Report) is a provider of integrated facility solutions. The Zacks Consensus Estimate for its current year earnings has been revised 2.1% downward over the last 30 days.
POST POSTZ ADUS POSTU POSHZ ABM UCTI 500570 TATAMOTORS UCTT TTM

4
Bear of the Day: The Cheesecake Factory (CAKE)

2018-08-14 zacks
Known, of course, for their decadent cheesecakes, The Cheesecake Factory (CAKE - Free Report) is a global restaurant company that owns and operates full-service, casual dining restaurants including the namesake The Cheesecake Factory, Grand Lux Café, and RockSugar Southeast Asian Kitchen.
FOX WYNN CSX UCTI RTN FOXA UCTT

10
Bear of the Day: Cars.com (CARS)

2018-08-13 zacks
The automotive industry is facing some headwinds right now. Rising interest rates certainly don’t help when consumers are out there looking for their next purchase. It can have buyers thinking about staying in their existing cars longer. There is a also a huge supply of used cars flooding the market and putting pressure on used car prices. That’s making used cars that much more attractive and forcing manufacturers to give huge incentives on new leases.
EXPE WYNN UCTI CARS UCTT

4
21st Century Fox (FOXA) Beats on Q4 Earnings and Revenues

2018-08-09 zacks
Twenty-First Century Fox, Inc. (FOXA - Free Report) reported fourth-quarter fiscal 2018 adjusted earnings of 57 cents, which beat the Zacks Consensus Estimate by 3 cents and increased 58.3% on a year-over-year basis. Revenues of $7.941 billion also came ahead of the consensus mark of $7.747 billion and increased 17.7% from the year-ago quarter. The impressive top-line figure was primarily attributable to increasing affiliate and advertising revenues from the Cable Network Programming and Television segments as well as improving content revenues at the Filmed Entertainment segment.
FOX CMCSA ZTO WTW UCTI FOXA UCTT

4
Nikon (NINOY) Q1 Earnings Beat Estimates, Revenues Down Y/Y

2018-08-09 zacks
Nikon (NINOY - Free Report) reported first-quarter fiscal 2019 earnings of 38 cents per share that beat the Zacks Consensus Estimate of 22 cents and is much higher than year-ago quarter figure of 20 cents. Revenues of ¥166 billion ($1.53 billion) decreased almost 2% year over year. Segment Details Imaging Products business’ revenues declined 13% year over year to ¥79.1 billion. The top line suffered from decline across all product lines.
ZTO UCTI NINOY INTC FTNT PAYC UCTT

29
Stock Market News For Aug 9, 2018

2018-08-09 zacks
U.S. stocks closed mostly lower on Wednesday. Renewed trade related conflicts between the United States and China resulting in imposition of retaliatory tariffs overshadowed strong earnings momentum. Both the Dow and S&P 500 ended in negative territory while Nasdaq Composite managed to finish in the green.
UCTI PZZA DIS SNAP UCTT

4
Norwegian Cruise Line (NCLH) Q2 Earnings Beat, Improve Y/Y

2018-08-09 zacks
Norwegian Cruise Line Holdings Ltd. (NCLH - Free Report) performed very well in the second quarter of 2018, reporting better-than-expected earnings per share and revenues. The company’s earnings (excluding 20 cents from non-recurring items) of $1.21 per share outpaced the Zacks Consensus Estimate of $1.03. The bottom line also increased 18.6% on a year-over-year basis. Higher revenues aided the quarterly results.
NCLH SEAS GES ZTO RCL UCTI UCTT

 
Monster Beverage (MNST) Q2 Earnings Top, Sales Lag Estimates

2018-08-09 zacks
Monster Beverage Corporation (MNST - Free Report) posted mixed second-quarter 2018 results, wherein the bottom line beat estimates while the top line missed. Both earnings and sales improved on a year-over-year basis. In the past three months, shares of this Zacks Rank #3 (Hold) company have gained 18.7%, outperforming the industry’s 13.2% rally.
ZTO MNST UCTI SAM UCTT

12
SINA Q2 Earnings Beat, Advertising Revenue Growth Solid

2018-08-09 zacks
SINA Corporation (SINA - Free Report) reported second-quarter 2018 non-GAAP earnings of 89 cents per share, which beat the Zacks Consensus Estimate of 71 cents and increased 27.1% from the year-ago quarter. Non-GAAP net revenues grew 50.1% to $534.8 million. Advertising revenues (84.5% of total revenues) surged 53.8% year over year to $454.1 million. Quarter Details The increase in advertising revenues was driven by growth in Weibo segment’s advertising and marketing revenues.
SINA ZTO STX VSH UCTI SAIC UCTT

1
Viacom (VIAB) Q3 Earnings Beat Estimates, Revenues Down Y/Y

2018-08-09 zacks
Viacom Inc. (VIAB - Free Report) reported third-quarter fiscal 2018 earnings of $1.18 per share that beat Zacks Consensus Estimate by 11 cents and increased 0.8% year over year. However, revenues of $3.24 billion lagged the Zacks Consensus Estimate of $3.27 billion and declined 4% year over year. Adjusted operating income declined 4.7% from the year-ago quarter to $767 million. Media Networks Details Media Networks revenues were $2.
VIA VIAB ZTO NFLX UCTI UCTT

137
How Will Rite Aid Be Impacted by Albertsons Deal Termination?

2018-08-09 zacks
Rite Aid Corporation (RAD - Free Report) and Albertsons have mutually agreed to call off their pending merger deal, in the best interest of shareholders. Following the termination, Rite Aid is likely to execute its strategic plan as a standalone company and is focused on leveraging its retail pharmacies, EnvisionRxOptions PBM as well as health and wellness offerings. Also, the company’s board of directors is making governance changes for enhancing its performance.
HLF RAD WBA UCTI UCTT

 
Low-Risk ETFs Taking Off on Rising Tariff Threats

2018-08-09 zacks
Though the U.S. stock market is advancing to the peak level it set in late January on surging corporate profits and an accelerating economy, trade tensions are blocking the road of the bulls. This is especially true as tensions between the world’s largest economies flared up once again this week (read: S&P 500 to Set New Records: Ride High With These ETFs). Escalating Trade Tensions In the latest development, China retaliated with additional tariffs of 25% on $16 billion worth of U.
DMRS USMV UCTI UCTT

8
NuStar's (NS) Q2 Earnings Miss Estimates, Revenues Beat

2018-08-09 zacks
NuStar Energy L.P. (NS - Free Report) recently reported second-quarter 2018 earnings per limited partner unit of 15 cents, missing the Zacks Consensus Estimate of 21 cents due to a fall in Storage segment income caused by increased operating costs. However, the reported figure surged from the year-ago earnings of 5 cents per unit, due to higher contributions from the partnership’s Permian Crude System.
COP CQP LNG CNQ NS UCTI LNG UCTT

 
Trump to Pass $717B Defense Budget Bill: Stocks to Watch

2018-08-09 zacks
President Donald Trump will travel to Fort Drum, New York, on Aug 13, to sign next year’s defense budget bill, which was promptly approved by Congress on Aug 1. The fiscal 2019 defense budget of $717 billion — the largest budget allotted to defense in U.S. history — gives a sense of the country’s seriousness in maintaining a solid security cover, when it has China and Russia as rivals.
LMT NOC OSK UCTI UCTT

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 90385V107